Aimen Aljoundi - Search Results

Year	Number of Results
2019	2
2020	2
2021	2
2022	7
2023	7
2024	1

1

Potential molecular mechanisms underlying the ameliorative effect of Cola nitida (Vent.) Schott & Endl. on insulin resistance in rat skeletal muscles.

Erukainure OL, Oyebode OA, Chuturgoon AA, Ghazi T, Muhammad A, Aljoundi A, Elamin G, Chukwuma CI, Islam MS. Erukainure OL, et al. Among authors: aljoundi a. J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117249. doi: 10.1016/j.jep.2023.117249. Epub 2023 Oct 6. J Ethnopharmacol. 2024. PMID: 37806534 Free article.

2

Investigation of Simultaneous and Sequential Cooperative Homotropic Inhibitor Binding to the Catalytic Chamber of SARS-CoV-2 RNA-dependent RNA Polymerase (RdRp).

Metwally K, Abo-Dya NE, Hamdan AME, Alrashidi MN, Alturki MS, Aly OM, Aljoundi A, Ibrahim M, Soliman MES. Metwally K, et al. Among authors: aljoundi a. Cell Biochem Biophys. 2023 Dec;81(4):697-706. doi: 10.1007/s12013-023-01163-y. Epub 2023 Sep 2. Cell Biochem Biophys. 2023. PMID: 37658974

3

Therapeutic Path to Triple Knockout: Investigating the Pan-inhibitory Mechanisms of AKT, CDK9, and TNKS2 by a novel 2-Phenylquinazolinone derivative in Cancer Therapy- An In-Silico Investigation.

Peters XQ, Elamin G, Aljoundi A, Alahmdi MI, Abo-Dya NE, Sidhom PA, Tawfeek AM, Ibrahim MAA, Soremekun O, Soliman MES. Peters XQ, et al. Among authors: aljoundi a. Curr Pharm Biotechnol. 2023 Aug 15. doi: 10.2174/1389201024666230815145001. Online ahead of print. Curr Pharm Biotechnol. 2023. PMID: 37581526

4

Enzyme-responsive biomimetic solid lipid nanoparticles for antibiotic delivery against hyaluronidase-secreting bacteria.

Mohammed M, Ibrahim UH, Aljoundi A, Omolo CA, Devnarain N, Gafar MA, Mocktar C, Govender T. Mohammed M, et al. Among authors: aljoundi a. Int J Pharm. 2023 Jun 10;640:122967. doi: 10.1016/j.ijpharm.2023.122967. Epub 2023 Apr 20. Int J Pharm. 2023. PMID: 37084831

5

The Unusual Architecture of RNA-Dependent RNA Polymerase (RdRp)'s Catalytic Chamber Provides a Potential Strategy for Combination Therapy against COVID-19.

Metwally K, Abo-Dya NE, Alahmdi MI, Albalawi MZ, Yahya G, Aljoundi A, Salifu EY, Elamin G, Ibrahim MAA, Sayed Y, Fanucchi S, Soliman MES. Metwally K, et al. Among authors: aljoundi a. Molecules. 2023 Mar 20;28(6):2806. doi: 10.3390/molecules28062806. Molecules. 2023. PMID: 36985777 Free PMC article.

6

Revealing the Role of the Arg and Lys in Shifting Paradigm from BTK Selective inhibition to the BTK/HCK Dual inhibition- Delving into the Inhibitory Activity of KIN-8194 Against BTK, and HCK in the Treatment of Mutated 〖BTK〗^Cys481 Waldenström Macroglobulinemia: A computational Approach.

Elamin G, Aljoundi A, Alahmdi M, Abo-Dya NE, Soliman M. Elamin G, et al. Among authors: aljoundi a. Anticancer Agents Med Chem. 2023 Feb 8. doi: 10.2174/1871520623666230208102609. Online ahead of print. Anticancer Agents Med Chem. 2023. PMID: 36752293

7

Molecular modelling of SdiA protein by selected flavonoid and terpenes compounds to attenuate virulence in Klebsiella pneumoniae.

Adeosun IJ, Baloyi I, Aljoundi AK, Salifu EY, Ibrahim MA, Cosa S. Adeosun IJ, et al. Among authors: aljoundi ak. J Biomol Struct Dyn. 2023 Nov;41(19):9938-9956. doi: 10.1080/07391102.2022.2148753. Epub 2022 Nov 23. J Biomol Struct Dyn. 2023. PMID: 36416609

8

Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.

Elamin G, Aljoundi A, Alahmdi MI, Abo-Dya NE, Soliman MES. Elamin G, et al. Among authors: aljoundi a. J Mol Model. 2022 Oct 12;28(11):355. doi: 10.1007/s00894-022-05345-y. J Mol Model. 2022. PMID: 36222928

9

Probing Alterations in MDM2 Catalytic Core Structure Effect of Garcinia Mangostana Derivatives: Insight from Molecular Dynamics Simulations.

El Habbash AI, Aljoundi A, Elamin G, Soliman MES. El Habbash AI, et al. Among authors: aljoundi a. Cell Biochem Biophys. 2022 Dec;80(4):633-645. doi: 10.1007/s12013-022-01101-4. Epub 2022 Oct 3. Cell Biochem Biophys. 2022. PMID: 36184717

10

Co-Binding of JQ1 and Venetoclax Exhibited Synergetic Inhibitory Effect for Cancer Therapy; Potential Line of Treatment for the Waldenström Macroglobulinemia Lymphoma.

Elamin G, Aljoundi A, Soliman MES. Elamin G, et al. Among authors: aljoundi a. Chem Biodivers. 2022 Jul;19(7):e202100845. doi: 10.1002/cbdv.202100845. Epub 2022 Jun 8. Chem Biodivers. 2022. PMID: 35610180

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

18 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year